pp 1-5 | Cite as
The Unique Spectrum of Mutations in Patients with Hereditary Tyrosinemia Type 1 in Different Regions of the Russian Federation
Background: Hereditary tyrosinemia (HT1) is an autosomal recessive disorder characterized by impaired tyrosine catabolism because of fumarylacetoacetate hydrolase deficiency. HT1 is caused by homozygous or compound heterozygous mutations in the FAH gene. The HT1 frequency worldwide is 1:100,000–1:120,000 live births. The frequency of HT1 in the Russian Federation is unknown.
Aim: To estimate the spectrum of mutations in HT1 in several ethnic groups of the Russian Federation.
Materials and methods: From 2004 to 2017, 43 patients were diagnosed with HT1. The analysis of amino acids and succinylacetone was performed using NeoGram Amino Acids and Acylcarnitines Tandem Mass Spectrometry Kit and a Sciex QTrap 3200 quadrupole tandem mass spectrometer. Bi-directional DNA sequence analysis was performed on PCR products using an ABI Prism 3500.
Results: In the Russian Federation, the most common mutation associated with HT1 (32.5% of all mutant alleles) is c.1025C>T (p.Pro342Leu), which is typical for the Chechen ethnic group. Patients of the Yakut, the Buryat, and the Nenets origins had a homozygous mutation c.1090G>C (p.Glu364Gln). High frequency of these ethnicity-specific mutations is most likely due to the founder effect. In patients from Central Russia, the splicing site mutations c.554-1G>T and c.1062+5G>A were the most prevalent, which is similar to the data obtained in the Eastern and Central Europe countries.
Conclusion: There are ethnic specificities in the spectrum of mutations in the FAH gene in HT1. The Chechen Republic has one of the highest prevalence of HT1 in the world.
KeywordsAllele Ethnicity Fumarylacetoacetate hydrolase deficiency Mutation Tyrosinemia type 1
- Allard P, Grenier A, Korson MS, Zytkovicz TH (2004) Newborn screening for hepatorenal tyrosinemia by tandem mass spectrometry: analysis of succinylacetone extracted from dried blood spots. Clin Biochem 37(11):1010–1015Google Scholar
- Bergeron A, D’Astous M, Timm DE, Tanguay RM (2001) Structural and functional analysis of missense mutations in fumarylacetoacetate hydrolase, the gene deficient in hereditary tyrosinemia type 1. J Biol Chem 276:15225–15231Google Scholar
- Bergman AJ, van den Berg IE, Brink W et al (1998) Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. Hum Mutat 12(1):19–26Google Scholar
- Bliksrud YT, Brodtkorb E, Backe PH et al (2012) Hereditary tyrosinaemia type I in Norway: incidence and three novel small deletions in the fumarylacetoacetase gene. Scand J Clin Lab Invest 72(5):369–373Google Scholar
- De Braekeeler M, Larochelle J (1990) Genetic epidemiology of hereditary tyrosinemia in Quebec and the Saguenay-Lac-St-Jean. Am J Hum Genet 47(2):302–307Google Scholar
- Dibirova KD, Balanovskaya EV, Kuznetzova MA et al (2010) Genetic topography of the Caucasus: four linguistic-geographical regions as indicated by data on chromosome Y polymorphism. Med Genet 10:10–14 (in Russian)Google Scholar
- Elpeleg ON, Shaag A, Holme E et al (2002) Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. Hum Mutat 19(1):80–81Google Scholar
- Endo F, Sun MS (2002) Tyrosinaemia type I and apoptosis of hepatocytes and renal tubular cells. J Inherit Metab Dis 25:227–234Google Scholar
- Maksimova NR, Gurinova EE, Sukhomyasova AL et al (2016) A novel homozygous mutation causing hereditary tyrosinemia type I in Yakut patient in Russia: case report. Wiad Lek 69(2 Pt 2):295–298Google Scholar
- McKiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosinaemia type 1. Drugs 66(6):743–750Google Scholar
- Mitchell GA, Grompe M, Lambert M, Tanguay RM (2001) Hypertyrosinemia. In: Scriver CR, Beaudet AL, Sly WS, Valle D (eds) The metabolic and molecular bases of inherited disease. McGraw Hill, New York, pp 1777–1806Google Scholar
- Nasrallah F, Hammami MB, Ben Rhouma H et al (2015) Clinical and biochemical profile of tyrosinemia type 1 in Tunisia. Clin Lab 61(5–6):487–492Google Scholar
- Novikov PV (2012) Tyrosinemia type I: clinical signs, diagnosis and treatment. Russ Bull Perinatol Pediatr S3:1–27 (in Russian)Google Scholar
- Polyakova SI (2012) Effectiveness of nitisinone therapy for hereditary tyrosinemia type I. Russ Pediatr J 6:59–60 (in Russian)Google Scholar
- Rootwelt H, Chou J, Gahl WA, Berger R, Coşkun T, Brodtkorb E, Kvittingen EA (1994) Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase. Hum Genet 93(6):615–619Google Scholar
- St-Louis M, Leclerc B, Laine J et al (1994) Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. Hum Mol Genet 3(1):69–72Google Scholar
- van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV et al (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20:1187–1191Google Scholar